BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28765916)

  • 21. Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System.
    Zhang M; Pan Y; Qi X; Liu Y; Dong R; Zheng D; Chang Q; Zhang J; Fang W; Zhong Y
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):101-107. PubMed ID: 27258564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
    Velázquez Vega JE; Brat DJ; Ryken TC; Olson JJ
    J Neurooncol; 2020 Nov; 150(2):143-164. PubMed ID: 33215342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
    Weller M; Felsberg J; Hartmann C; Berger H; Steinbach JP; Schramm J; Westphal M; Schackert G; Simon M; Tonn JC; Heese O; Krex D; Nikkhah G; Pietsch T; Wiestler O; Reifenberger G; von Deimling A; Loeffler M
    J Clin Oncol; 2009 Dec; 27(34):5743-50. PubMed ID: 19805672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme.
    Zhu H; Woolfenden S; Bronson RT; Jaffer ZM; Barluenga S; Winssinger N; Rubenstein AE; Chen R; Charest A
    Mol Cancer Ther; 2010 Sep; 9(9):2618-26. PubMed ID: 20643786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The preliminary radiogenomics association between MR perfusion imaging parameters and genomic biomarkers, and their predictive performance of overall survival in patients with glioblastoma.
    Liu X; Mangla R; Tian W; Qiu X; Li D; Walter KA; Ekholm S; Johnson MD
    J Neurooncol; 2017 Dec; 135(3):553-560. PubMed ID: 28889246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins.
    Shimamura T; Lowell AM; Engelman JA; Shapiro GI
    Cancer Res; 2005 Jul; 65(14):6401-8. PubMed ID: 16024644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Chamberlain MC; Sanson M
    Neurology; 2015 May; 84(19):2007. PubMed ID: 25964481
    [No Abstract]   [Full Text] [Related]  

  • 28. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
    Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
    Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
    Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune checkpoint molecule herpes virus entry mediator is overexpressed and associated with poor prognosis in human glioblastoma.
    Han MZ; Wang S; Zhao WB; Ni SL; Yang N; Kong Y; Huang B; Chen AJ; Li XG; Wang J; Wang DH
    EBioMedicine; 2019 May; 43():159-170. PubMed ID: 30987862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.
    Heimberger AB; Hlatky R; Suki D; Yang D; Weinberg J; Gilbert M; Sawaya R; Aldape K
    Clin Cancer Res; 2005 Feb; 11(4):1462-6. PubMed ID: 15746047
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors.
    Layfield LJ; Willmore C; Tripp S; Jones C; Jensen RL
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):91-6. PubMed ID: 16540738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
    Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
    Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
    Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
    Front Immunol; 2022; 13():869061. PubMed ID: 36248907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.
    Mock A; Geisenberger C; Orlik C; Warta R; Schwager C; Jungk C; Dutruel C; Geiselhart L; Weichenhan D; Zucknick M; Nied AK; Friauf S; Exner J; Capper D; Hartmann C; Lahrmann B; Grabe N; Debus J; von Deimling A; Popanda O; Plass C; Unterberg A; Abdollahi A; Schmezer P; Herold-Mende C
    Int J Cancer; 2016 Jul; 139(2):424-32. PubMed ID: 26934681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development.
    Brown KE; Chagoya G; Kwatra SG; Yen T; Keir ST; Cooter M; Hoadley KA; Rasheed A; Lipp ES; Mclendon R; Ali-Osman F; Bigner DD; Sampson JH; Kwatra MM
    J Neurochem; 2015 Jun; 133(5):730-8. PubMed ID: 25598002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epilysin is overexpressed in glioblastoma and related to clinical outcome of patients.
    Wang X; Zhang K; Chen X; Zhao C; Sun Z
    Med Oncol; 2015 Jan; 32(1):363. PubMed ID: 25429835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exome sequencing identifies frequent genomic loss of TET1 in IDH-wild-type glioblastoma.
    Stasik S; Juratli TA; Petzold A; Richter S; Zolal A; Schackert G; Dahl A; Krex D; Thiede C
    Neoplasia; 2020 Dec; 22(12):800-808. PubMed ID: 33142244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Multifunctional Role of EMP3 in the Regulation of Membrane Receptors Associated with IDH-Wild-Type Glioblastoma.
    Martija AA; Pusch S
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.